Hepatitis C through the lens of Correctional Health Services
Prevalence of HCV antibody positivity in the NYC jails was estimated to be 12.5% in 2006 (internal serosurvey data), however case identification varied based on provider practice and facility. In 2013, a policy promoting birth-cohort screening in addition to risk factor screening was implemented. Average monthly testing increased from approximately 400 tests per month in May 2013 to over 1000 tests per month in October 2013. In July 2014, a pilot program to evaluate universal rapid testing was conducted in the largest facility in the system, one which also houses a population with a higher prevalence of substance use and mental health disorders. During the three month pilot 1305 patients received rapid HCV testing and overall prevalence in this high risk population was estimated to be 23%. Based on an expected treatment cost of $70,000 per course of treatment, the cost of averaging just ten patients on treatment daily is three million dollars per year. The burden of HCV infection in the jails is also reflected in its clinical impact. Review of all medical deaths from 2012 through 2014 found that HCV was comorbid in 68% (19/28) and was the primary cause of death in 25% (7/28). Though a small sample, this appears to be a higher rate of HCV related death when compared with data from 2001-2009 demonstrating that liver disease accounted for 4.5% of deaths in the NYC jail system (Brittain 2013).
The high prevalence of HCV in jails has major implications for screening practices, costs and patient outcomes. While there is opportunity to scale up treatment, significantly increased funding or decreased treatment prices will be necessary to mitigate the burden of the disease for our patients and the system in coming years.
Learning Areas:Chronic disease management and prevention
Clinical medicine applied in public health
Conduct evaluation related to programs, research, and other areas of practice
Planning of health education strategies, interventions, and programs
Protection of the public in relation to communicable diseases including prevention or control
Analyze, through a variety of measures, how hepatitis C (HCV) impacts the health care system in the New York City jails. Describe the disease burden of HCV in the New York City jails Assess the financial impact of HCV screening and treatment practices in the New York City jails Analyze the changing clinical implications of hepatitis C in the New York City jails
Keyword(s): Prisoners Health, Hepatitis C
Qualified on the content I am responsible for because: As Deputy Medical Director for Correctional Health Services of the New York City Department of Health and Mental Hygiene I help oversee care throughout the NYC jail system. I help oversee the quality of care throughout the system and develop policies around medical care including communicable diseases. The NYC jail system includes 12,000 patients in 12 jails on an average day and has a high prevalence of hepatitis C and substance abuse.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.